Brief: Paratek Pharmaceuticals Announces FDA Approval Of Nuzyra (Omadacycline) Oral Only Dosing Regimen For The Treatment Of Community-Acquired Bacterial Pneumonia (Cabp)
01/06/2021 12:48
June 1 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NUZYRA®
(OMADACYCLINE) ORAL ONLY DOSING REGIMEN FOR THE TREATMENT OF
COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP)
Source text for Eikon: ID:nGNXbhyK7N
Further company coverage: PRTK.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million